JOP20190179A1 - نوكليوتيدات ثنائية حلقية كناهضات لـ sting - Google Patents

نوكليوتيدات ثنائية حلقية كناهضات لـ sting

Info

Publication number
JOP20190179A1
JOP20190179A1 JOJO/P/2019/0179A JOP20190179A JOP20190179A1 JO P20190179 A1 JOP20190179 A1 JO P20190179A1 JO P20190179 A JOP20190179 A JO P20190179A JO P20190179 A1 JOP20190179 A1 JO P20190179A1
Authority
JO
Jordan
Prior art keywords
sting agonists
bicyclic nucleotides
sting
formula
compounds
Prior art date
Application number
JOJO/P/2019/0179A
Other languages
English (en)
Inventor
Emanuel Stuart
Beigelman Leonid
J Connolly Peter
Bignan Gilles
P Edwards James
Kumar Thatikonda Santhosh
Wang Guangyi
Viellevoye Marcel
Richter Mark
Bert Griet Schepens Wim
Wilhelmus J F Thuring Johannes
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of JOP20190179A1 publication Critical patent/JOP20190179A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يكشف الاختراع عن مركبات وتركيبات وطرق لعلاج أمراض أو متلازمات أو اضطرابات تتأثر بتعديل فاعلية STING. ويتم تمثيل مثل هذه المركبات بالصيغة (I) على النحو التالي: الصيغة (I) حيث إن R1 و R1’ و X1 و B1 و R2 و R2’ و B2 و X2 و R3 وZ-M-Y و Y1-M1-Z1 يتم تعريفها بهذه الوثيقة.
JOJO/P/2019/0179A 2018-07-17 2019-07-16 نوكليوتيدات ثنائية حلقية كناهضات لـ sting JOP20190179A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862699001P 2018-07-17 2018-07-17

Publications (1)

Publication Number Publication Date
JOP20190179A1 true JOP20190179A1 (ar) 2020-01-17

Family

ID=67999987

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2019/0179A JOP20190179A1 (ar) 2018-07-17 2019-07-16 نوكليوتيدات ثنائية حلقية كناهضات لـ sting

Country Status (21)

Country Link
US (2) US11597746B2 (ar)
EP (1) EP3823976A1 (ar)
JP (1) JP2021531277A (ar)
KR (1) KR20210033026A (ar)
CN (1) CN112424212A (ar)
AR (1) AR122240A1 (ar)
AU (1) AU2019304230B2 (ar)
BR (1) BR112021000693A2 (ar)
CA (1) CA3106602A1 (ar)
EA (1) EA202190298A1 (ar)
EC (1) ECSP21003171A (ar)
IL (1) IL280105A (ar)
JO (1) JOP20190179A1 (ar)
MA (1) MA53178A (ar)
MX (1) MX2021000625A (ar)
PE (1) PE20211636A1 (ar)
PH (1) PH12020552172A1 (ar)
SG (1) SG11202012624RA (ar)
TW (1) TW202030199A (ar)
UY (1) UY38304A (ar)
WO (1) WO2020016782A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712509A (zh) * 2017-12-15 2020-09-25 詹森生物科技公司 作为sting激动剂的环状二核苷酸
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
EP4704829A2 (en) * 2023-04-26 2026-03-11 Lakewood Amedex, Inc. Substituted bicyclic heterocycle compounds, compositions, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849084B (zh) * 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
US10723756B2 (en) * 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
KR102789862B1 (ko) * 2016-01-11 2025-04-03 인네이트 튜머 이뮤니티, 인코포레이티드 Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
NZ746112A (en) * 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
IL264049B2 (en) * 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, preparations and methods for treating the disease
US20190345191A1 (en) * 2016-08-31 2019-11-14 Innate Tumor Immunity, Inc. Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
JOP20170188A1 (ar) * 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸

Also Published As

Publication number Publication date
SG11202012624RA (en) 2021-02-25
WO2020016782A1 (en) 2020-01-23
PE20211636A1 (es) 2021-08-24
UY38304A (es) 2020-01-31
MA53178A (fr) 2021-05-26
AU2019304230A1 (en) 2021-01-14
KR20210033026A (ko) 2021-03-25
CN112424212A (zh) 2021-02-26
CA3106602A1 (en) 2020-01-23
MX2021000625A (es) 2021-03-25
US11597746B2 (en) 2023-03-07
AR122240A1 (es) 2022-08-31
AU2019304230B2 (en) 2023-08-31
BR112021000693A2 (pt) 2021-04-13
PH12020552172A1 (en) 2021-06-07
IL280105A (en) 2021-03-01
US20210277046A1 (en) 2021-09-09
EA202190298A1 (ru) 2021-04-16
EP3823976A1 (en) 2021-05-26
ECSP21003171A (es) 2021-02-26
TW202030199A (zh) 2020-08-16
JP2021531277A (ja) 2021-11-18
US20230287034A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
PH12021551065A1 (en) Fused ring compounds
PH12021500014A1 (en) Fused ring compounds
EA202091709A1 (ru) Ингибиторы днк-пк
EA202091708A1 (ru) Ингибиторы днк-пк
MX2021013197A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
MX392673B (es) Derivados de pirazol como inhibidores de malt1
EA202092086A1 (ru) Ингибиторы аргиназы
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX380907B (es) Compuestos útiles como inhibidores de cinasa.
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
EA201990400A1 (ru) Соединения и композиции и их применение
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201890256A1 (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
JOP20190179A1 (ar) نوكليوتيدات ثنائية حلقية كناهضات لـ sting
EA201991898A1 (ru) Двойные ингибиторы magl и faah
PH12017502123A1 (en) Substituted benzamides and methods of use thereof
MX380677B (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2021013602A (es) Inhibidores de jak.
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
UA117779C2 (uk) Піразини як модулятори gpr6
BR112022005608A2 (pt) Inibidores de jak